12/11 Stock To Watch -------- LXRX

[Vincent]

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the
discovery and development of pharmaceutical products for the treatment of
human disease, including immunology, metabolism, cardiology, and
ophthalmology. The company?s drug candidates include LX1031, which is in a
Phase II clinical trial for the treatment of irritable bowel syndrome and
other gastrointestinal disorders; LX1032 that has completed Phase I clinical
trials to treat the symptoms associated with carcinoid syndrome; LX2931,
which is in Phase I clinical trial for the treatment of rheumatoid arthritis
and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials
to treat Type 2 diabetes. It also has a preclinical development drug
candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals
has drug discovery alliances with Bristol-Myers Squibb Company to discover,
develop, and commercialize small molecule drugs in the neuroscience field;
and N.V. Organon to discover, develop, and commercialize new biotherapeutic
drugs. It also has an alliance with Nuevolution A/S, which provides access
to Nuevolution?s Chemetics platform chemistry technology. The company was
founded in 1995 and is headquartered in The Woodlands, Texas.